FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials
The FDA’s Oncologic Drugs Advisory Committee on Thursday unanimously backed the need to change trial designs in perioperative non-small cell lung cancer, highlighting the need to clearly elucidate the contributions of investigational treatments when given …